The Latest Cardiac and Vascular News
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not […]
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced topline results from the Phase 1b single-ascending dose study of MYK-491. MYK-491 was generally well-tolerated and increases in cardiac contractility were […]
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that Taylor Harris, Chief Financial Officer, will present at the BMO 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018, […]
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, presented preclinical data at the American Heart Association (AHA) Scientific Sessions 2018 that demonstrated that targeting the heart’s motor protein, myosin, improved ventricular […]
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018. “MyoKardia continues to make encouraging progress toward our mission of changing the […]
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer, will provide a corporate update at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November […]
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced new clinical data describing mavacamten’s effect on diastolic function will be presented at the upcoming American Heart Association (AHA) Scientific Sessions […]
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc., (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, announced a comprehensive update on its clinical-stage and emerging pipeline today at its 2018 R&D Day in New York City. Among the highlights: […]
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that patient dosing has begun in the MAVA Long-Term Extension (MAVA-LTE) clinical trial. The MAVA-LTE study will assess long-term safety of […]
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it will host a Research and Development (R&D) Day for analysts and investors on Tuesday, October 30, 2018 beginning at […]
Notifications
